News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Optimizing Outcomes in HR+/HER2-Metastatic Breast Cancer: Molecular Testing and Targeted Strategies

EP. 1: Clinical Perspectives on Biomarker Testing in mBC

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 2: Repeat Biomarker Testing in mBC: Navigating the Rapidly Evolving Treatment Landscape

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 3: Selecting the Optimal CDK4/6 Regimen for First-Line Therapy

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 4: Clinical Considerations for CDK4/6 Inhibition Beyond Progression

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 5: Expert Insights: Managing Patients with PIK3CA Mutations

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 6: Navigating Treatment Selection in Patients with Both ESR1 and PIK3CA Mutations and Expert Perspective for Integrating Oral SERDs into Clinical Practice

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 7: The Emerging Role of Triplet Therapy in mBC: Opportunities and Challenges

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

EP. 8: The Evolving Landscape of mBC Treatment: Unmet Needs and Future Predictions

ByJoyce O’Shaughnessy, MD,Alison Conlin, MD

March 6th 2025

Trending on OncLive

ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC

FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer

Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC

Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026

HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer